GRAIL, Inc. - GRAL STOCK NEWS

GRAIL announced the first patient testing in the global TROPION-Lung12 Phase 3 study using their Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay. The study, conducted under FDA approval, evaluates adjuvant treatments in Stage I adenocarcinoma NSCLC patients. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo.

GRAIL's blood-based methylation platform detects ctDNA without requiring tissue analysis, streamlining integration into clinical trials. Patients will be screened pre-surgery to determine eligibility for post-surgery treatment. This marks one of the first uses of ctDNA assay in early-stage lung cancer trials to identify patients who may benefit from additional treatment.

GRAIL (GRAL) reported Q3 2024 financial results with total revenue of $28.7 million, up 38% year-over-year. Galleri revenue grew 52% to $25.4 million, with over 250,000 tests sold since launch. The company posted a net loss of $(125.7) million, including $34.6 million in amortization and $19.0 million in restructuring charges. Gross loss was $(22.2) million, while adjusted gross profit reached $11.8 million. The company maintains a strong cash position of $853.6 million, providing runway into 2028.

GRAIL (Nasdaq: GRAL) has announced its upcoming participation at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The company's management will deliver a presentation on Thursday, November 21 at 11:00 a.m. ET. The event will be accessible via live and replay webcasts through GRAIL's investor relations website section at investors.grail.com, with recordings available for at least 30 days following the presentation.

GRAIL (Nasdaq: GRAL) has scheduled the release of its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and business progress. Interested parties can access the live webcast and replay through the investor relations section at investors.grail.com, with registration available at the provided link. Participants are advised to register and join ten minutes before the scheduled start time.

GRAIL announced initial results from the REFLECTION study evaluating the Galleri® multi-cancer early detection (MCED) test in veterans. The study, conducted across seven VA sites, showed a cancer signal detection rate of 1.30% (37/2854 participants) among veterans with toxic exposure, consistent with other populations. Of 28 participants completing 180-day follow-up, 12 cancer diagnoses were confirmed, with over half identified at early stages (I-III). The test demonstrated a positive predictive value of 42.9%. The study included veterans aged ≥22 years (mean age 60), with 70% exposed to toxic hazards during service. Lung cancer was the most common cancer signal detected.

GRAIL, Inc. (Nasdaq: GRAL) has announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Krevans will serve on the Board's Audit, Compensation, and Nominating and Governance Committees. With her addition, the Board now consists of five directors, four of whom are independent.

Krevans served as president and CEO of Sutter Health from 2016 to 2022, overseeing an integrated network of 14,000 clinicians, 24 hospitals, and various healthcare services. Her leadership focused on advancing clinical programs, innovation, and digital health to improve patient accessibility.

Bob Ragusa, CEO of GRAIL, expressed confidence in Krevans' ability to bring valuable experience to GRAIL's mission of establishing a new standard for multi-cancer early detection. Krevans' extensive healthcare background includes executive roles at Kaiser Permanente and in Maine's healthcare administration. She holds master's degrees in business administration and public health from UC Berkeley and has been recognized as one of the top healthcare leaders by Modern Healthcare.

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced the granting of equity awards to 55 recently hired non-executive employees. These awards, in the form of restricted stock units (RSUs) totaling 182,223 shares of GRAIL's common stock, were granted under the company's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs are designed to vest over approximately four years, with 25% vesting in either May or August 2025, depending on the employee's start date, and the remaining vesting annually thereafter. This vesting schedule is subject to continued employment with GRAIL or its subsidiaries.

GRAIL, Inc. (Nasdaq: GRAL) has published findings on the performance of its Galleri® multi-cancer early detection (MCED) test for prostate cancer in JCO Precision Oncology. The data, from the CCGA and PATHFINDER studies, show that Galleri preferentially detects aggressive, clinically significant prostate cancers over slow-growing cases.

Key findings include:

• 93% of detected prostate cancers were intermediate or high grade
• 67% were stage III or IV
• Cancer signal of origin prediction accuracy was >90%
• No low-grade cancers were detected
• Only 4.2% of stage I and II cancers were detected

These results suggest that Galleri could be valuable in population-based screening programs without contributing to overdiagnosis of indolent prostate cancers.

GRAIL, a healthcare company focused on early cancer detection, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will present on September 4, 2024, at 3:20 p.m. ET. Investors and interested parties can access both live and replay webcasts of the presentation through GRAIL's investor relations website at investors.grail.com. The webcast will remain available for replay for at least 30 days after the event, providing an opportunity for those unable to attend live to catch up on GRAIL's latest updates and insights.